NovoCure Ltd Annual Income Tax Expense (Benefit) in USD from 2013 to 2023
-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
-
Summary
-
NovoCure Ltd quarterly/annual Income Tax Expense (Benefit) history and growth rate from 2013 to 2023.
- NovoCure Ltd Income Tax Expense (Benefit) for the quarter ending September 30, 2024 was $8.99M, a 611% increase year-over-year.
- NovoCure Ltd Income Tax Expense (Benefit) for the twelve months ending September 30, 2024 was $35.3M, a 207% increase year-over-year.
- NovoCure Ltd annual Income Tax Expense (Benefit) for 2023 was $15.3M, a 43.2% increase from 2022.
- NovoCure Ltd annual Income Tax Expense (Benefit) for 2022 was $10.7M, a 70.3% increase from 2021.
- NovoCure Ltd annual Income Tax Expense (Benefit) for 2021 was $6.28M.
Income Tax Expense (Benefit), Trailing 12 Months (USD)
Income Tax Expense (Benefit), Annual (USD)
Income Tax Expense (Benefit), YoY Annual Growth (%)